Enoxaparin and Dabigatran Thromboprophylaxis after Total Hip Arthroplasty



如何引用文章

全文:

详细

Comparative assessment of the efficacy and safety of enoxaparin and dabigatran thromboprophylaxis after total hip arthroplasty was performed. Hemorrhagic and thrombotic complications as well as indices of laboratory tests after application of new oral thrombin inhibitor Dabigatran Etexilate were taken into account. Study included 161 patients who were randomized into two groups and operated on under spinal anesthesia. First group (81 patients) was on subcutaneous enoxaparin (40 mg/day), second group (80) was on dagibartan (200 mg/day). The day before surgery and on 5th and 10th days after arthroplasty duplex angioscanning of lower extremities and assessment of blood clotting parameters was performed. It was shown that in case of significant intraoperative blood loss thromboprophylaxis with both enoxaparin and dabigatran was similar to that with low-molecular-weight heparin. Postoperative thrombogenic risk by D-dimers level was higher with enoxaparin versus dabigatran application. Peroral use of anticoagulants is more acceptable due to its noninvasiveness, safety, low requirements in laboratory monitoring and convenience of application in out-patient conditions. In patients with low compliance testing of blood plasma thrombin can be used for the confirmation of dabigatran intake when necessary.

参考

  1. Баркаган З.С., Момот А.П. Диагностика и контролируемая терапия нарушений гемостаза. - М., 2008.
  2. Воробьев А.И., Городецкий В.М. Трансфузионная терапия острой массивной кровопотери и анемии //Очерки по производственной и клинической трансфузиологии /Под ред. А.И. Воробьева. - М., 2006. - С. 383-397.
  3. Копенкин С.С. Профилактика венозных тромбоэмболических осложнений в ортопедической хирургии: новые возможности //Вестн. травматол. ортопед. - 2010. - N 1. - С. 35-38.
  4. Приказ Минздрава РФ от 25 ноября 2002 г. № 363 "Об утверждении Инструкции по применению компонентов крови".
  5. Руководство по гематологии. - Т. 3 /Под ред. А.И. Воробьева. - 3-е изд. - М., 2005.
  6. Савельев В.С., Чазов Е.И., Гусев Е.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений //Флебология. - 2010. - Т. 4, вып. 2. - С. 3-37.
  7. Савельев В.С., Гологорский В.А., Кириенко А.И. и др. Флебология: Руководство для врачей /Под ред. В.С. Савельева. - М., 2001.
  8. Хорев Н.Г., Момот А.П., Залозный Д.А. Новые оральные антикоагулянты (обзор литературы) //Фарматека. - 2010. - N 18/19. - С. 20-26.
  9. Abrams P.J., Emerson C.R. Rivaroxaban: A novel, oral, direct factor Xa inhibitor //Pharmacotherapy. - 2009. - Vol. 29, N 2. - P. 167-181.
  10. Anderson F.A., Hirsh J., White K., Fitzgerald R. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry //Chest. - 2003. - N 124. - P. 349-356.
  11. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial //Lancet. - 2007. - N 370. - P. 949-956.
  12. Geerts W.H., Pineo G.F., Heit H.A. et al. Prevention of venous thromboembolism //Chest. - 2008. - N 133. - P. 381-453.
  13. Russell D., Roger D., Bergqvist D. Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis //Clin. Appl. Thromb. Hemostasis. - 2009. - Vol. 15, N 4. - P. 377-388.
  14. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate //Clin. Pharmacokinet. - 2008. - Vol. 47. - P. 285-295.
  15. Van Ryn J., Stangier J., Haertter S. et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity //Thrombosis and Haemostasis. - 2010. - Vol. 103. - N 6. - P. 1116-1127.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2011


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-76249 от 19.07.2019.


##common.cookie##